Skip to main content

Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.

Publication ,  Journal Article
Gockerman, JP; Silberman, H; Bartolucci, AA
Published in: Cancer Treat Rep
1987

Duke Scholars

Published In

Cancer Treat Rep

ISSN

0361-5960

Publication Date

1987

Volume

71

Issue

7-8

Start / End Page

773 / 774

Location

United States

Related Subject Headings

  • Naphthacenes
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Evaluation
  • Clinical Trials as Topic
  • Antibiotics, Antineoplastic
  • Aclarubicin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gockerman, J. P., Silberman, H., & Bartolucci, A. A. (1987). Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep, 71(7–8), 773–774.
Gockerman, J. P., H. Silberman, and A. A. Bartolucci. “Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.Cancer Treat Rep 71, no. 7–8 (1987): 773–74.
Gockerman JP, Silberman H, Bartolucci AA. Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1987;71(7–8):773–4.
Gockerman, J. P., et al. “Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.Cancer Treat Rep, vol. 71, no. 7–8, 1987, pp. 773–74.
Gockerman JP, Silberman H, Bartolucci AA. Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1987;71(7–8):773–774.

Published In

Cancer Treat Rep

ISSN

0361-5960

Publication Date

1987

Volume

71

Issue

7-8

Start / End Page

773 / 774

Location

United States

Related Subject Headings

  • Naphthacenes
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Evaluation
  • Clinical Trials as Topic
  • Antibiotics, Antineoplastic
  • Aclarubicin